Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 3/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.38 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.36 |
| ▸ | GSK3B | P49841 | 4/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.36 |
| ▸ | WNT1 | P04628 | 3/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | JUN | P05412 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4454293 | 0.83 | MAPK8 (0.43) | MAPK10MAPK8MAPK9IRAK4IRAK1 | |
| SCHEMBL2281187 | 0.82 | IRAK4 (0.37) | MAPK10MAPK8MAPK9IRAK4IRAK1 | |
| SCHEMBL12404256 | 0.81 | MAPK10 (0.50) | MAPK10MAPK8MAPK9IRAK4IRAK1 | |
| SCHEMBL12404260 | 0.81 | MAPK10 (0.50) | MAPK10MAPK8MAPK9IRAK4IRAK1 | |
| SCHEMBL4457136 | 0.80 | MAPK8 (0.46) | MAPK10MAPK8MAPK9IRAK4IRAK1 | |
| SCHEMBL12406850 | 0.76 | KDR (0.37) | — | |
| SCHEMBL4465826 | 0.73 | ACVR1 (0.44) | MAPK10MAPK8MAPK9IRAK4ACVR1 | |
| SCHEMBL12652520 | 0.71 | IRAK4 (0.43) | IRAK4PIK3CDACVR1 | |
| SCHEMBL12404156 | 0.71 | MAPK8 (0.42) | MAPK10MAPK8MAPK9IRAK4IRAK1 | |
| SCHEMBL2753432 | 0.70 | MAPK8 (0.66) | MAPK10MAPK8MAPK9IRAK4LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195951-A1 | DIAZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195951-A1 | DIAZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | DAPK1, DAPK2, DAPK3 | MAPK10 77/4885MAPK8 53/4885MAPK9 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.